Journal of Kidney Cancer and VHL

metrics 2024

Catalyzing progress in VHL research and treatment.

Introduction

The Journal of Kidney Cancer and VHL stands as a leading platform for disseminating cutting-edge research in the field of renal oncology, particularly focused on kidney cancer and Von Hippel-Lindau (VHL) disease. Published by CODON PUBLICATIONS since its inception, this Open Access journal, with ready accessibility since 2014, aims to foster knowledge exchange and collaboration among researchers, clinicians, and healthcare professionals dedicated to improving outcomes for patients with kidney cancer. With an ISSN of 2203-5826, this journal serves as a vital resource in the academic community, encouraging submissions that span various topics, including epidemiology, treatment modalities, and innovative therapeutic strategies. By providing unrestricted access to its content, the Journal of Kidney Cancer and VHL promotes inclusive participation in the global dialogue surrounding these critical health challenges, ensuring that the latest findings reach all corners of the scientific community.

Metrics 2024

SCIMAGO Journal Rank-
Journal Impact Factor1.90
Journal Impact Factor (5 years)1.90
H-Index-
Journal IF Without Self1.90
Eigen Factor0.00
Normal Eigen Factor0.05
Influence0.46
Immediacy Index0.50
Cited Half Life4.20
Citing Half Life8.20
JCI0.32
Total Documents-
WOS Total Citations235
SCIMAGO Total Citations-
SCIMAGO SELF Citations-
Scopus Journal Rank-
Cites / Document (2 Years)-
Cites / Document (3 Years)-
Cites / Document (4 Years)-

Metrics History

Rank 2024

IF (Web Of Science)

ONCOLOGY
Rank 234/322
Percentile 27.50
Quartile Q3

JCI (Web Of Science)

ONCOLOGY
Rank 263/322
Percentile 18.32
Quartile Q4

Quartile History

Similar Journals

Chinese Clinical Oncology

Fostering collaboration in the fight against cancer.
Publisher: AME PUBLISHING COMPANYISSN: 2304-3865Frequency: 4 issues/year

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

NEPHROLOGY

Pioneering insights into kidney health and groundbreaking treatments.
Publisher: WILEYISSN: 1320-5358Frequency: 12 issues/year

NEPHROLOGY is a leading academic journal published by Wiley, dedicated to advancing research and discussions in the fields of Nephrology and Medicine. With an ISSN of 1320-5358, this journal has consistently demonstrated its significance and impact, reflecting a Q2 category ranking in both Medicine (miscellaneous) and Nephrology as of 2023. Covering a comprehensive range of topics since its inception in 1995, NEPHROLOGY provides a vital platform for researchers, practitioners, and students alike to explore the latest advancements, innovative treatments, and diverse challenges within the field. Although it does not operate under an open access model, the journal remains highly regarded, with a commendable Scopus rank of #27 out of 81 in Nephrology, positioning it in the 67th percentile among its peers. Located in the United Kingdom, NEPHROLOGY invites submissions that push the boundaries of knowledge, ultimately striving to enhance the understanding of renal health and disease.

AMERICAN JOURNAL OF NEPHROLOGY

Exploring breakthroughs in renal research since 1981.
Publisher: KARGERISSN: 0250-8095Frequency: 12 issues/year

The American Journal of Nephrology, published by KARGER, stands as a prestigious platform for the dissemination of high-quality research in the field of nephrology, boasting an impressive Q1 ranking in its category as of 2023. With its ISSN 0250-8095 and E-ISSN 1421-9670, the journal has been committed to advancing knowledge in kidney diseases since its inception in 1981. It serves as an essential resource for researchers, clinicians, and students alike, featuring original articles, reviews, and case reports that contribute to the understanding and treatment of renal conditions. Despite not being an open-access journal, the American Journal of Nephrology ensures a rigorous peer-review process to maintain its high academic standards, making it a vital source of information for the nephrology community worldwide. By providing insights into emerging trends and breakthroughs in kidney health, the journal continues to play a crucial role in shaping the future of nephrology research.

Cancer Research and Treatment

Unveiling the future of oncology research.
Publisher: KOREAN CANCER ASSOCIATIONISSN: 1598-2998Frequency: 4 issues/year

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

Hematology Reports

Advancing knowledge in blood disorders.
Publisher: MDPIISSN: 2038-8322Frequency: 4 issues/year

Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.

PATHOLOGY & ONCOLOGY RESEARCH

Advancing the Frontiers of Cancer Research
Publisher: FRONTIERS MEDIA SAISSN: 1219-4956Frequency: 1 issue/year

PATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.

Molecular and Clinical Oncology

Innovating cancer care through rigorous research.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

European Urology Oncology

Elevating the standards of urological oncology research.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Kidney International Reports

Elevating research standards in kidney health and disease.
Publisher: ELSEVIER SCIENCE INCISSN: 2468-0249Frequency: 12 issues/year

Kidney International Reports, published by ELSEVIER SCIENCE INC, stands as a premier open-access journal in the realm of nephrology, having established itself since its inception in 2016. This scholarly platform, with an ISSN of 2468-0249, is dedicated to presenting high-quality research and critical reviews that advance our understanding of kidney health and disease. With a remarkable Q1 ranking in nephrology and a notable position within the top 10 of Scopus rankings for this specialty, the journal is a pivotal resource for researchers, healthcare professionals, and students alike. Featuring a broad scope of topics from clinical nephrology to innovative treatment strategies, Kidney International Reports ensures accessibility to the latest findings through its open access model, making it instrumental in promoting knowledge sharing and collaboration across the global nephrology community. The journal's commitment to excellence not only enhances the visibility of research but also fosters the development of effective treatments and therapies for kidney diseases.

Renal Society of Australasia Journal

Elevating the discourse in nephrology and urology globally.
Publisher: RENAL SOC AUSTRALASIAISSN: 1832-3804Frequency: 3 issues/year

Renal Society of Australasia Journal, published by the Renal Society of Australasia, serves as a crucial platform for disseminating cutting-edge research and insights within the fields of nephrology and urology. With its ISSN of 1832-3804, this journal has been continually published since 2011, showcasing the evolving landscape of renal health in Australia and beyond. Despite currently holding a Q4 ranking in both nephrology and urology categories, the journal is committed to supporting the scientific community with rigorous peer-reviewed articles that enhance clinical practice and foster research advancement. As an open access journal, it aims to provide wide visibility and access to researchers, professionals, and students alike, thus promoting knowledge sharing among various stakeholders in renal health. Positioned within a global context, it addresses local health challenges while contributing to the broader discourse in renal sciences, making it an essential resource for those dedicated to improving patient outcomes in this critical area of medicine.